Abstract：Objective To study the clinical features of children with relapsed acute lymphoblastic leukemia (ALL) treated with the CCLG-ALL2008 protocol. Methods The data of 591 children who were newly diagnosed with ALL and were treated with the CCLG-ALL 2008 protocol between April 2008 and June 2013 were collected, and the clinical features of 80 children with relapsed ALL were retrospectively analyzed. Results After treatment with the CCLGALL2008 protocol, the recurrence rate in the standard-risk, intermediate-risk and the high-risk groups were 7.0%, 10.7% and 28.7% respectively (P<0.05). The recurrence rate in patients with TEL/AML1-positive ALL was 8.0%, and the 5-year overall survival (OS) of the relapsed patients was 37.04%. The recurrence rates in patients with MLL-positive and BCR/ABL-positive ALL were 35.0% and 24.2% respectively, and none of the relapsed patients had long-term survival. The recurrence mainly occurred at the very early stage (53%), and none of patients with recurrence at the very early stage had long-term survival. The recurrence occurred at early stage and late stage accounted for 34% and 14% respectively, and the 5-year OS rates of patients with recurrence at early stage and late stage were 11.44% and 60.00% respectively. The sites of recurrence were mainly bone marrow alone (83%), and the 5-year OS of patients with recurrence at bone marrow alone was 9.23%. The recurrence in bone marrow and outside bone marrow accounted for 11%, and the 5-year OS of patients with recurrence in both bone marrow and outside bone marrow was 25.00%. The recurrence only outside bone marrow accounted for 6%, and the 5-year OS of patients with recurrence only outside bone marrow was 100%. The recurrence rate in patients with T-cell ALL was 9.5%, and none of the relapsed patients had long-term survival. The recurrence rate in patients with B-cell ALL was 14.3%, and the 5-year OS of the relapsed patients was 15.52%. Conclusions After treatment with the CCLG-ALL2008 protocol, a relatively high recurrence rate is observed in children with high-risk ALL. Positive MLL and positive BCR/ABL are high-risk factors for recurrence. The recurrence rate is not significantly correlated with immunophenotype. A very low survival rate is seen in children whose recurrence have the following features: at early stage, only in bone marrow, T-cell ALL, and abnormal BCR/ABL and MLL.
CHEN Xiao-Juan,ZOU Yao,YANG Wen-Yu et al. Clinical features of children with relapsed acute lymphoblastic leukemia treated with the CCLG-ALL2008 protocol[J]. CJCP, 2015, 17(4): 321-326.
Pui CH. Recent research advances in childhood acute lymphoblastic leukemia[J]. J Formos Med Assoc, 2010, 109(11): 777-787.
[5]
Nguyen K, Devidas M, Cheng SC, et al. Factors influencing survival after relapse from acute lymphoblastic leukemia: a Children’s Oncology Group study[J]. Leukemia, 2008, 22(12): 2142-2150.
[6]
Tharnprisan P, Khiewyoo J, Sripraya P, et al. Relapse-free rate with childhood acute lymphoblastic leukemia treated under the thai national protocol[J]. Asian Pac J Cancer Prev, 2013, 14(2): 1127-1130.
Pui CH, Campana D, Pei D, et al. Treatment of childhood acute lymphoblastic leukemia without prophylactic cranial irradiation[J]. N Engl J Med, 2009, 360(26): 2730-2741.
[9]
Cancela CS, Murao M, Viana MB, et al. Incidence and risk factors for central nervous system relapse in children and adolescents with acute lymphoblastic leukemia[J]. Rev Bras Hematol Hemoter, 2012, 34(6): 436-441.
[10]
Locatelli F, Schrappe M, Bernardo ME, et al. How I treat relapsed childhood acute lymphoblastic leukemia[J]. Blood, 2012, 120(14): 2807-2816.
[11]
Pui CH, Howard SC. Current management and challenges of malignant disease in the CNS in paediatric leukaemia[J]. Lancet Oncol, 2008, 9(3): 257-268.
[12]
Pui CH, Thiel E. Central nervous system disease in hematologic malignancies: historical perspective and practical applications[J]. Semin Oncol, 2009, 36(4 Suppl 2): S2-S16.
[13]
Jorgensen M, Shankar A, Aabideen Z, et al. The role of routine surveillance for silent central nervous system relapse in children with acute lymphoblastic leukaemia[J]. Br J Haematol, 2012, 159(3): 368-370.
[14]
Kawedia JD, Liu C, Pei D, et al. Dexamethasone exposure and asparaginase antibodies affect relapse risk in acute lymphoblastic leukemia[J]. Blood, 2012, 119(7): 1658-1664.
[15]
Pui CH, Mullighan CG, Evans WE, et al. Pediatric acute lymphoblastic leukemia: where are we going and how do we get there?[J]. Blood, 2012, 120(6): 1165-1174.
[16]
Pui CH, Pei D, Campana D, et al. A revised definition for cure of childhood acute lymphoblastic leukemia[J]. Leukemia, 2014, 28(12): 2336-2343.
[17]
Marjerrison S, Antillon F, Fu L, et al. Outcome of children treated for relapsed acute lymphoblastic leukemia in Central America[J]. Cancer, 2013, 119(6): 1277-1283.
[18]
Pulsipher MA, Peters C, Pui CH. High-risk pediatric acute lymphoblastic leukemia: to transplant or not to transplant? [J]. Biol Blood Marrow Transplant, 2011, 17(1 Suppl): S137-S148.
Burke MJ, Lamba JK, Pounds S, et al. A therapeutic trial of decitabine and vorinostat in combination with chemotherapy for relapsed/refractory acute lymphoblastic leukemia[J]. Am J Hematol, 2014, 89(9): 889-895.
[21]
Yang JJ, Cheng C, Devidas M, et al. Genome-wide association study identifies germline polymorphisms associated with relapse of childhood acute lymphoblastic leukemia[J]. Blood, 2012, 120(20): 4197-4204.
[22]
Gómez-Gómez Y, Organista-Nava J, Saavedra-Herrera MV, et al. Survival and risk of relapse of acute lymphoblastic leukemia in a Mexican population is affected by dihydrofolate reductase gene polymorphisms[J]. Exp Ther Med, 2012, 3(4): 665-672.
[23]
Meyer JA, Wang J, Hogan LE, et al. Relapse-specific mutations in NT5C2 in childhood acute lymphoblastic leukemia[J]. Nat Genet, 2013, 45(3): 290-294.
[24]
Lo Nigro L. Biology of childhood acute lymphoblastic leukemia[J]. J Pediatr Hematol Oncol, 2013, 35(4): 245-252.
[25]
Dandekar S, Romanos-Sirakis E, Pais F, et al. Wnt inhibition leads to improved chemosensitivity in paediatric acute lymphoblastic leukaemia[J]. Br J Haematol, 2014, 167(1): 87- 99.
[26]
Knight T, Irving JA. Ras/Raf/MEK/ERK pathway activation in childhood acute lymphoblastic leukemia and its therapeutic targeting[J]. Front Oncol, 2014, 4: 160.
[27]
Roti G, Stegmaier K. New approaches to target T-ALL[J]. Front Oncol, 2014, 4: 170.
[28]
Bhatla T, Jones CL, Meyer JA, et al. The biology of relapsed acute lymphoblastic leukemia: opportunities for therapeutic interventions[J]. J Pediatr Hematol Oncol, 2014, 36(6): 413-418.
